Obermatt
See Similar Stocks →

Stoke Therapeutics

NSQ:STOK · US86150R1077
BiotechnologySmall

360

16
Profit price66
Owner Earnings Yield1
Dividend Yield1
Price/Sales36
EV / Gross Profit5
Price/Book7
Return on Capital36
Cash Return on Capital50
Return on Equity48
Profit margins52
Accruals9
Owner Earnings Margin23
Sales growth10
Profit Growth27
Long-Term EPS Growth25
Reinvestment60
Price momentum84
Debt load82
Refinancing51
Debt Payback1
Liquidity1
Analyst ratings81
Opinion Changes50
Price Target Upside38
Market mood70
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Stoke Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2014
Employees174
Websitestoketherapeutics.com
ISINUS86150R1077
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsOphthalmologyNeurologyCentral Nervous SystemNeuroscienceGenetic DisorderBiotechnologyHealth CarePharmaceuticalTherapeutics

Description

Stoke Therapeutics, Inc. operates as a late-stage clinical-stage company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Au…

Analysis

Hope premium

Stoke Therapeutics, Inc. is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

Valuation data is not available for this company.

Growth is tepid; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
25
2026

All-time high

37

Mar 2026

All-time low

25

Jun 2026

Average rank

31

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
36
—
—
—
Price/Earnings
76
—
—
—
Price/Book
7
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
1
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Stoke Therapeutics with its peers
Quest Diagnostics
NYQ:DGX
35
CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Benitec Biopharma
NAQ:BNTC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tenaya Therapeutics
NSQ:TNYA
29
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vor Biopharma
NSQ:VOR
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Design Therapeutics
NSQ:DSGN
71
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MeiraGTx
NSQ:MGTX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →